Against that background, even with new, lowered regulatory bar for new therapeutics, it seems unlikely that approval would occur after studies of a dozen patients (the size of the study, as listed on clinicaltrials.gov).

FORBES: Sarepta Outperformed Biotechs In August Due To Muscular Dystrophy Drug

Previously, the trial bar could use the testimony of people who did not have the background to speak knowledgeably about the subject at hand.

FORBES: Fact and Comment